Q1 EPS Forecast for Axsome Therapeutics Lowered by Analyst

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Equities researchers at HC Wainwright reduced their Q1 2025 earnings estimates for Axsome Therapeutics in a research report issued on Thursday, February 20th. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($1.06) per share for the quarter, down from their previous estimate of ($0.85). HC Wainwright has a “Buy” rating and a $200.00 price target on the stock. The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($2.74) per share. HC Wainwright also issued estimates for Axsome Therapeutics’ Q2 2025 earnings at ($0.72) EPS, Q3 2025 earnings at ($0.37) EPS, Q4 2025 earnings at $0.21 EPS, FY2025 earnings at ($1.93) EPS, Q2 2026 earnings at $1.16 EPS, Q3 2026 earnings at $2.43 EPS and Q4 2026 earnings at $3.82 EPS.

A number of other analysts also recently issued reports on the stock. Bank of America increased their target price on shares of Axsome Therapeutics from $143.00 to $167.00 and gave the stock a “buy” rating in a research report on Tuesday, February 11th. Truist Financial boosted their price objective on shares of Axsome Therapeutics from $190.00 to $200.00 and gave the stock a “buy” rating in a research note on Wednesday, February 19th. StockNews.com raised shares of Axsome Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. Leerink Partners upped their price target on shares of Axsome Therapeutics from $110.00 to $150.00 and gave the stock an “outperform” rating in a research report on Monday, February 10th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $153.00 price target on shares of Axsome Therapeutics in a report on Wednesday, February 19th. One research analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $158.79.

Axsome Therapeutics Stock Performance

Shares of NASDAQ:AXSM opened at $137.75 on Monday. The business has a 50-day moving average of $101.29 and a two-hundred day moving average of $94.99. The firm has a market capitalization of $6.72 billion, a PE ratio of -23.00 and a beta of 1.05. The company has a debt-to-equity ratio of 3.22, a current ratio of 2.11 and a quick ratio of 2.37. Axsome Therapeutics has a 12 month low of $64.11 and a 12 month high of $139.13.

Axsome Therapeutics (NASDAQ:AXSM) last issued its earnings results on Tuesday, February 18th. The company reported ($0.96) earnings per share for the quarter, topping the consensus estimate of ($0.97) by $0.01. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%. The business had revenue of $118.77 million for the quarter, compared to analyst estimates of $117.83 million.

Institutional Trading of Axsome Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. TFG Asset Management GP Ltd bought a new position in Axsome Therapeutics during the 4th quarter valued at $3,490,000. GF Fund Management CO. LTD. bought a new position in shares of Axsome Therapeutics during the fourth quarter worth about $86,000. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. acquired a new position in Axsome Therapeutics in the fourth quarter worth about $2,853,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in Axsome Therapeutics by 20.8% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 57,642 shares of the company’s stock valued at $4,877,000 after buying an additional 9,928 shares during the last quarter. Finally, Woodline Partners LP raised its stake in Axsome Therapeutics by 36.8% during the fourth quarter. Woodline Partners LP now owns 408,441 shares of the company’s stock valued at $34,558,000 after buying an additional 109,872 shares in the last quarter. Institutional investors own 81.49% of the company’s stock.

Insider Activity at Axsome Therapeutics

In other Axsome Therapeutics news, CFO Nick Pizzie sold 3,000 shares of the company’s stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $131.07, for a total value of $393,210.00. Following the transaction, the chief financial officer now directly owns 42,187 shares of the company’s stock, valued at $5,529,450.09. This represents a 6.64 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 22.40% of the stock is currently owned by company insiders.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.